Martina Buscema

Dr. Martina Buscema


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Benedetta BondiBenedetta Bondi
Benedetta Bondi
MBMartina Buscema
Martina Buscema
FMFederico Di Marco
Federico Di Marco
CCCarlo Conti
Carlo Conti
ACAndrea Caviglia
Andrea Caviglia
DBDiego Bagnasco
Diego Bagnasco
The diagnosis and management of UAD require an integrated, multidisciplinary approach. Diagnostic strategies combine clinical evaluation, imaging (CT), allergy testing, biomarker measurement (such as FeNO, blood eosinophils, IgE), and pulmonary function testing (spirometry, IOS) to phenotype the disease. Therapeutic management is stratified and aims to control inflammation and symptoms in both compartments. Cornerstones include topical corticosteroids (intranasal and inhaled) and saline irrigations. For severe forms, especially T2-high, targeted biologic therapies (anti-IL-5/IL-5R, anti-IL-4R, anti-TSLP) have revolutionized treatment, reducing dependence on oral corticosteroids and the need for surgical interventions (like endoscopic sinus surgery, ESS). Adopting a "treatable traits" approach is emerging as a key strategy for precision medicine in UAD.